Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 217Active not recruiting 101Completed 42Not yet recruiting 39Terminated 21Suspended 7Withdrawn 2Enrolling by invitation 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Dermatologic 1Breast 1

Conditions

Neoplasms 31Prostatic Neoplasms 13Breast Neoplasms 13Colorectal Neoplasms 12Hematologic Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lung Neoplasms 6Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Uterine Cervical Neoplasms 4Pancreatic Neoplasms 4Myasthenia Gravis 4Melanoma 4Lymphoma, Non-Hodgkin 4Leukemia, Myeloid, Acute 4Head and Neck Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Adenocarcinoma 4Pain 3Ovarian Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Hematopoietic and Lymphatic System Neoplasm 3Hematologic Diseases 3Glioma 3Gastrointestinal Neoplasms 3Carcinoma, Renal Cell 3Brain Neoplasms 3Anxiety Disorders 3Urinary Bladder Neoplasms 2

Interventions

futibatinib 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Enrolling by invitation × Neoplasm Metastasis × 90 days × Clear all
NCT06506955 2026-05-28

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Taiho Oncology, Inc.

Phase 2/3 Enrolling by invitation
15 enrolled
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT00068003 2026-05-01

Harvesting Cells for Experimental Cancer Treatments

National Institutes of Health Clinical Center (CC)

Enrolling by invitation
7,000 enrolled
BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡